New drug hope for rare joint tumor patients who Can't have surgery
NCT ID NCT04703322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called pexidartinib (TURALIO) in 9 Japanese adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and limits movement. The goal was to see if the drug is safe and can shrink tumors in people whose tumors are too severe or risky to remove with surgery. Participants took 800 mg of pexidartinib daily, and researchers measured tumor response using MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pexidartinib (TURALIO)
What this could lead to
If successful, this could provide a non-surgical treatment option for people with TGCT who have severe symptoms and cannot have surgery.
What could go wrong
This is a small, early-phase study with only 9 participants, so results may not apply to everyone. Pexidartinib can cause serious side effects, including liver injury.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kanazawa University Hospital
Ishikawa, 920-8641, Japan
-
Kyushu University Hospital
Fukuoka, 812-8582, Japan
-
Nagoya University Hospital
Aichi, 466-8560, Japan
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Hospital Organization Osaka National Hospital
Osaka, 540-0006, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan